← Back to Search

Corticosteroid

TRS01 for Anterior Uveitis

Phase 3
Waitlist Available
Research Sponsored by Tarsier Pharma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days
Awards & highlights

Summary

This trial is testing a new eye drop for people with active non-infectious anterior uveitis, with or without uveitic glaucoma.

Eligible Conditions
  • Anterior Uveitis
  • Uveitic Glaucoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Anterior Chamber Cell (ACC) grade on Day 28
Secondary outcome measures
Anterior Chamber Cell (ACC) grade on Day 21
Change from baseline (Day 1) in ACC Grade on Day 28 in the study eye
Change from baseline in ACC Grade on Day 21.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: TRS01Experimental Treatment1 Intervention
Group II: Active comparatorActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TRS01
2021
Completed Phase 3
~150

Find a Location

Who is running the clinical trial?

Tarsier PharmaLead Sponsor
2 Previous Clinical Trials
53 Total Patients Enrolled
Lexitas Clinical TrialsStudy DirectorLexitas
~38 spots leftby Jul 2025